Document Detail


Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.
MedLine Citation:
PMID:  20200251     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Respiratory syncytial virus (RSV) is the main cause of bronchiolitis, the major cause of hospitalization of infants. An ideal RSV vaccine would be effective for neonates, but the immune responses of infants differ markedly from those of adults, often showing a bias toward T-helper 2 (Th2) responses and reduced gamma interferon (IFN-gamma) production. We previously developed recombinant RSV vectors expressing IFN-gamma and interleukin-4 (IL-4) that allow us to explore the role of these key Th1 and Th2 cytokines during infection. The aim of the current study was to explore whether an immunomodulation of infant responses could enhance protection. The expression of IFN-gamma by a recombinant RSV vector (RSV/IFN-gamma) attenuated primary viral replication in newborn mice without affecting the development of specific antibody or T-cell responses. Upon challenge, RSV/IFN-gamma mice were protected from the exacerbated disease observed for mice primed with wild-type RSV; however, antiviral immunity was not enhanced. Conversely, the expression of IL-4 by recombinant RSV did not affect virus replication in neonates but greatly enhanced Th2 immune responses upon challenge without affecting weight loss. These studies demonstrate that it is possible to manipulate infant immune responses by using cytokine-expressing recombinant viruses and that neonatal deficiency in IFN-gamma responses may lead to enhanced disease during secondary infection.
Authors:
James A Harker; Debbie C P Lee; Yuko Yamaguchi; Belinda Wang; Alexander Bukreyev; Peter L Collins; John S Tregoning; Peter J M Openshaw
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't     Date:  2010-03-03
Journal Detail:
Title:  Journal of virology     Volume:  84     ISSN:  1098-5514     ISO Abbreviation:  J. Virol.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-22     Completed Date:  2010-05-04     Revised Date:  2010-11-02    
Medline Journal Info:
Nlm Unique ID:  0113724     Medline TA:  J Virol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5294-302     Citation Subset:  IM    
Affiliation:
Department of Respiratory Medicine, the Centre for Respiratory Infection and MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, St. Mary's Campus, London W2 1PG, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Viral / blood
Body Weight
Female
Interferon-gamma / genetics,  immunology*
Lung / immunology*,  virology
Mice
Mice, Inbred BALB C
Pregnancy
Respiratory Syncytial Virus Infections / immunology,  pathology,  prevention & control*
Respiratory Syncytial Virus Vaccines / genetics,  immunology*
Respiratory Syncytial Viruses / genetics,  immunology*
T-Lymphocytes / immunology
Vaccines, Synthetic / genetics,  immunology
Grant Support
ID/Acronym/Agency:
071381/Z/03/Z//Wellcome Trust; //Medical Research Council
Chemical
Reg. No./Substance:
0/Antibodies, Viral; 0/Respiratory Syncytial Virus Vaccines; 0/Vaccines, Synthetic; 82115-62-6/Interferon-gamma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phenotypic and Functional Profile of HIV-inhibitory CD8 T cells Elicited by Natural Infection and He...
Next Document:  A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influ...